Breaking News Instant updates and real-time market news.

BLUE

Bluebird Bio

$119.90

-4 (-3.23%)

, NVS

Novartis

$89.70

0.11 (0.12%)

12:40
06/14/19
06/14
12:40
06/14/19
12:40

Price tag of Bluebird's Zynteglo 'hard to justify,' says Piper Jaffray

The $1.8M price tag of Bluebird Bio's Zynteglo is "hard to justify" given the $2.1M comp of Novartis' (NVS) Zolgensma, which treats children with a certain outcome of death, as opposed to a population where the majority of patients are adequately maintained on transfusions, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. In Zynteglo clinical trials, only 60 beta-thal patients have been enrolled and 16 sickle cell patients have ever been infused, the analyst points out. Yet, says Van Buren, the Street is modeling that Bluebird transplants thousands of patients with Zynteglo. He continues to believe uptake of the gene therapy will be challenging and keeps a Neutral rating on Bluebird Bio with a $120 price target.

BLUE

Bluebird Bio

$119.90

-4 (-3.23%)

NVS

Novartis

$89.70

0.11 (0.12%)

  • 14

    Jun

BLUE Bluebird Bio
$119.90

-4 (-3.23%)

05/15/19
WEDB
05/15/19
DOWNGRADE
WEDB
Neutral
Bluebird Bio downgraded to Neutral from Outperform at Wedbush
05/15/19
05/15/19
DOWNGRADE
Target $131

Neutral
Bluebird Bio downgraded to Neutral at Wedbush on ZYNTEGLO launch risks
As previously reported, Wedbush analyst David Nierengarten downgraded Bluebird Bio to Neutral from Outperform after attending the company's Analyst Day, as he sees risks to the ZYNTEGLO launch that could overshadow its broad pipeline. Specifically, the analyst now expects installment, performance-based pricing of $320,000/year, in-line with annual treatment costs, for 5 years, or $1.6M total, with a 15% discount on the total potential price as some patients will not fully respond/meet the performance requirements. With installment pricing, Nierengarten incorporates additional financing in his model as it creates an "air gap" for cash flow that the company will have to fill before it becomes cash flow positive. The analyst also lowered his price target on the shares to $131 fr0m $166.
05/16/19
RHCO
05/16/19
NO CHANGE
Target $174
RHCO
Buy
Bluebird Bio price target lowered to $174 from $184 at SunTrust
SunTrust analyst Edward Nash lowered his price target on Bluebird Bio to $174 to reflect the changes in his model after the company's Analyst Day presentation. The analyst is pushing back his expected Lenti-D start year to 2020 from 2019 and also raising his assumed R&D and SG&A expenses while also removing the revenue projections for the company's B-thalassemia patients aged below 12 in the U.S. and E.U. Nash is also keeping his Buy rating on Bluebird Bio, saying he sees the company as "best positioned" in transforming gene therapy from a "scientific endeavor" to a "successful proposition."
05/17/19
JPMS
05/17/19
NO CHANGE
Target $195
JPMS
Overweight
Bluebird Bio 20% pullback since early April brings opportunity, says JPMorgan
JPMorgan analyst Cory Kasimov thinks investors should use times of share weakness to buy or add to longer-term positions in Bluebird Bio. With the stock off nearly 20% since early April, "this could be one of those times," Kasimov tells investors in a research note. He believes Bluebird has a relatively high likelihood of going four-for-four with its initial late-stage shots on goal. The analyst maintains an Overweight rating on the shares with a $195 price target.
NVS Novartis
$89.70

0.11 (0.12%)

05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.
05/24/19
FBCO
05/24/19
NO CHANGE
FBCO
Underperform
Zolgensma label breadth on higher end of expectations, says Credit Suisse
Credit Suisse analyst Evan Seigerman noted that the FDA announced approval for Novartis' (NVS) Zolgensma for the treatment of Spinal Muscular Atrophy, or SMA, in patients with bi-allelic mutations in the SMN1 gene under 2 years of age. The current wholesale acquisition cost for Biogen's (BIIB) Spinraza equates to a per-year treatment cost of $500,000 for the first year loading phase and $250,000-$375,000 per year for maintenance thereafter, which compares to a WAC of $2.125M for Zolgensma, which is administered just once, noted Seigerman. While investors generally expected Zolgensma would be approved, the breadth of the label was on the higher end of expectations, Seigerman tells investors. The pricing and label support his below consensus view of Spinraza, as he continues to expect that Zolgensma will become the preferred first option for infant-onset type 1 SMA, said the analyst, who reiterates his $198 price target and Underperform rating on Biogen shares.
06/03/19
06/03/19
DOWNGRADE

Perform
Aduro Biotech downgraded to Perform on lack of catalysts at Oppenheimer
As previously reported, Oppenheimer analyst Mark Breidenbach downgraded Aduro Biotech (ADRO) to Perform from Outperform given the company's lack of near-term catalysts. The analyst notes that Aduro's partner Novartis (NVS) presented initial clinical results from an ongoing Phase 1b trial of ADU-S100 in combination with spartalizumab in advanced tumors at ASCO. Given the pretreatment history of these patients, he cannot state with confidence that the responses observed were dependent on ADUS100, and the trial data suggests dosing has not yet been fully optimized. As Novartis continues to evaluate the STING agonist, Breidenbach anticipates an extended development timeline.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

, GRUB

GrubHub

$70.15

-2.76 (-3.79%)

13:28
06/15/19
06/15
13:28
06/15/19
13:28
Periodicals
Amazon exit gives GrubHub stock boost, Barron's says »

Amazon (AMZN) is…

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

, CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

13:20
06/15/19
06/15
13:20
06/15/19
13:20
Periodicals
McKesson, Cardinal Health looking like bargains, Barron's says »

Investors have halved the…

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

MCK

McKesson

$133.19

-1.7 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

RTN

Raytheon

$177.38

0.195 (0.11%)

, UTX

United Technologies

$125.30

0.45 (0.36%)

13:09
06/15/19
06/15
13:09
06/15/19
13:09
Periodicals
United Technologies, Raytheon stocks looking cheap, Barron's says »

Shares of United…

RTN

Raytheon

$177.38

0.195 (0.11%)

UTX

United Technologies

$125.30

0.45 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

, AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

13:04
06/15/19
06/15
13:04
06/15/19
13:04
Periodicals
Food fight extending well beyond restaurant delivery, Barron's says »

Amazon (AMZN) is quitting…

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

GOOGL

Alphabet Class A

$1,086.36

-4.65 (-0.43%)

, GOOG

Alphabet

$1,085.56

-3.52 (-0.32%)

12:59
06/15/19
06/15
12:59
06/15/19
12:59
Periodicals
Facebook, JPMorgan chiefs among Best CEOs of 2019, Barron's says »

Separated into three…

GOOGL

Alphabet Class A

$1,086.36

-4.65 (-0.43%)

GOOG

Alphabet

$1,085.56

-3.52 (-0.32%)

FB

Facebook

$181.35

3.88 (2.19%)

MCD

McDonald's

$205.33

0.85 (0.42%)

JPM

JPMorgan

$109.84

0.26 (0.24%)

BAC

Bank of America

$28.03

0.09 (0.32%)

BLK

BlackRock

$446.96

-1.29 (-0.29%)

BX

Blackstone

$44.13

0.17 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 09

    Jul

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

  • 06

    Aug

  • 27

    Oct

AVGO

Broadcom

$265.99

-15.96 (-5.66%)

, AAPL

Apple

$192.84

-1.93 (-0.99%)

07:17
06/15/19
06/15
07:17
06/15/19
07:17
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AVGO

Broadcom

$265.99

-15.96 (-5.66%)

AAPL

Apple

$192.84

-1.93 (-0.99%)

HNHPF

Hon Hai Precision

$0.00

(0.00%)

UTX

United Technologies

$125.30

0.45 (0.36%)

RTN

Raytheon

$177.38

0.195 (0.11%)

CGC

Canopy Growth

$41.15

-0.64 (-1.53%)

TLRY

Tilray

$38.96

-1.78 (-4.37%)

APHA

Aphria

$6.80

-0.15 (-2.16%)

ACB

Aurora Cannabis

$7.56

(0.00%)

CVSI

CV Sciences

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

CRON

Cronos Group

$15.43

-0.92 (-5.63%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.28

0.4201 (48.85%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

ZYNE

Zynerba

$13.03

-0.54 (-3.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

  • 18

    Jun

  • 19

    Jun

  • 21

    Jun

  • 25

    Jun

  • 09

    Jul

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, ABMD

Abiomed

$250.96

-4.58 (-1.79%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
International League of Dermatological Societies to hold a conference »

24th World Congress of…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

ABMD

Abiomed

$250.96

-4.58 (-1.79%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

LLY

Eli Lilly

$111.74

-0.06 (-0.05%)

JNJ

Johnson & Johnson

$140.08

-0.63 (-0.45%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PG

Procter & Gamble

$111.20

0.28 (0.25%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

UL

Unilever; also tag UN

$62.61

-0.07 (-0.11%)

UN

Unilever; also tag UL

$61.30

-0.13 (-0.21%)

INCY

Incyte

$77.76

1.385 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 26

    Jun

  • 27

    Jun

  • 16

    Jul

  • 25

    Jul

  • 30

    Jul

  • 28

    Aug

  • 03

    Sep

  • 16

    Sep

  • 13

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

, GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
European Congress of Rheumatology to hold a conference »

EULAR 2019 will be held…

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

PFE

Pfizer

$42.75

0.24 (0.56%)

LLY

Eli Lilly

$111.74

-0.06 (-0.05%)

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

RHHBY

Roche

$0.00

(0.00%)

BIIB

Biogen

$227.67

-3.57 (-1.54%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

REGN

Regeneron

$305.19

-2.235 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 25

    Jul

  • 30

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

ABT

Abbott

$82.25

-0.03 (-0.04%)

, AMGN

Amgen

$176.09

-0.74 (-0.42%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
Society for Vascular Surgery to hold annual meeting »

SVS Annual Meeting 2019…

ABT

Abbott

$82.25

-0.03 (-0.04%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

BSX

Boston Scientific

$40.41

-0.26 (-0.64%)

PFE

Pfizer

$42.75

0.24 (0.56%)

CRY

CryoLife

$29.13

-0.13 (-0.44%)

EW

Edwards Lifesciences

$184.00

-0.63 (-0.34%)

ELGX

Endologix

$7.61

0.2 (2.70%)

IAC

IAC

$228.41

-2.63 (-1.14%)

HCA

HCA Healthcare

$126.64

-0.76 (-0.60%)

LMAT

LeMaitre

$26.04

-0.44 (-1.66%)

ORGO

Organogenesis

$7.39

0.02 (0.27%)

OSIR

Osiris

$0.00

(0.00%)

PEN

Penumbra

$166.75

2.93 (1.79%)

SWAV

ShockWave Medical

$58.27

-0.99 (-1.67%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 26

    Jun

  • 09

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 16

    Sep

  • 25

    Sep

  • 13

    Nov

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jun

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

CNC

Centene

$53.52

-0.26 (-0.48%)

, WCG

WellCare

$287.16

0.145 (0.05%)

18:45
06/14/19
06/14
18:45
06/14/19
18:45
Hot Stocks
Centene CEO: Medicare for all will not work »

In an interview on…

CNC

Centene

$53.52

-0.26 (-0.48%)

WCG

WellCare

$287.16

0.145 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

HMC

Honda

$25.34

-0.405 (-1.57%)

18:24
06/14/19
06/14
18:24
06/14/19
18:24
Hot Stocks
Honda recalls all 2016-2019 model year Pioneer vehicles »

Honda is conducting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$111.28

1.42 (1.29%)

18:22
06/14/19
06/14
18:22
06/14/19
18:22
Hot Stocks
RH CEO: We think our stock is massively undervalued »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$37.54

-0.35 (-0.92%)

, S

Sprint

$7.01

0.2 (2.94%)

18:08
06/14/19
06/14
18:08
06/14/19
18:08
Periodicals
Dish leads bidding for Sprint, T-Mobile assets, WSJ reports »

Dish Network (DISH) is…

DISH

Dish

$37.54

-0.35 (-0.92%)

S

Sprint

$7.01

0.2 (2.94%)

TMUS

T-Mobile

$74.90

0.44 (0.59%)

CHTR

Charter

$392.20

2.76 (0.71%)

ATUS

Altice USA

$23.82

0.15 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$32.69

-0.39 (-1.18%)

17:31
06/14/19
06/14
17:31
06/14/19
17:31
Periodicals
American Air asks court to end 'devastating' work slowdown, Bloomberg says »

American Airlines urged a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROLL

RBC Bearings

$150.43

-3.38 (-2.20%)

17:16
06/14/19
06/14
17:16
06/14/19
17:16
Hot Stocks
RBC Bearings CEO sells over 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNW

FTE Networks

$1.25

(0.00%)

17:14
06/14/19
06/14
17:14
06/14/19
17:14
Hot Stocks
FTE Networks granted financial viability exception by NYSE regulation »

FTE Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$347.19

-1.54 (-0.44%)

17:14
06/14/19
06/14
17:14
06/14/19
17:14
Hot Stocks
Boeing awarded Air Force contract modification, increases ceiling by $6.53B »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

MDR

McDermott

$7.60

-0.12 (-1.55%)

17:11
06/14/19
06/14
17:11
06/14/19
17:11
Hot Stocks
Chatterjee Fund Management reports 5.6% passive stake in McDermott »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$50.74

0.28 (0.55%)

17:09
06/14/19
06/14
17:09
06/14/19
17:09
Hot Stocks
Papa John's dismisses KPMG as auditors, hires Ernst & Young »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 13

    Nov

EPZM

Epizyme

$11.62

-0.36 (-3.01%)

16:55
06/14/19
06/14
16:55
06/14/19
16:55
Conference/Events
Epizyme to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

CACI

CACI

$202.80

-1.205 (-0.59%)

16:54
06/14/19
06/14
16:54
06/14/19
16:54
Conference/Events
CACI to hold a conference call »

Management holds a fiscal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

HCR

Hi-Crush Inc.

$2.84

0.115 (4.22%)

16:53
06/14/19
06/14
16:53
06/14/19
16:53
Syndicate
Hi-Crush Inc files $1B mixed securities shelf »

The company also files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHIP

Seanergy Marine

$0.63

-0.0381 (-5.70%)

16:51
06/14/19
06/14
16:51
06/14/19
16:51
Earnings
Seanergy Marine reports Q1 EPS ($3.23), two estimates ($2.85) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FELP

Foresight Energy

$0.79

-0.04 (-4.82%)

16:46
06/14/19
06/14
16:46
06/14/19
16:46
Hot Stocks
Foresight Energy discloses NYSE listing standard notice »

Foresight Energy is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.